Clinical Trials Logo

Antiemetic clinical trials

View clinical trials related to Antiemetic.

Filter by:
  • None
  • Page 1

NCT ID: NCT05564286 Completed - Cervical Cancer Clinical Trials

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Start date: July 1, 2021
Phase: Phase 3
Study type: Interventional

The study is to evaluate the antiemetic effect of adding fosaprepitant to biplet regimen of tropisetron and dexamethasone for patients with cervical cancer or nasopharyngeal cancer treated with radiotherapy and concomitant weekly cisplatin chemotherapy in a south Chinese cohort.

NCT ID: NCT04576390 Not yet recruiting - Clinical trials for Postoperative Nausea and Vomiting

Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing ERCP

Start date: October 24, 2020
Phase: Phase 4
Study type: Interventional

This study is designed to compare the effects of a single dose Ondansetron 4mg versus Palonosetron 75mcg in the prophylaxis against early & delayed postoperative nausea and vomiting in the first 48 hours post-operatively in patients undergoing Endoscopic Retrograde Cholangio-Pancreatography (ERCP) to determine the complete response, complete control and failure rates.

NCT ID: NCT00502437 Not yet recruiting - Antiemetic Clinical Trials

The Antigagging Effect of Granisetron (Kytril), an Antiemetic Drug, in Dental Situations

Start date: n/a
Phase: N/A
Study type: Interventional

Antigagging effect of kytril (granisetron) an antiemetic drug in dental situations Gagging in dental situations can be a problem to the patient and the operating dentist. There are not proven methods of eliminating this reflex which sometimes will not allow routine quality dental care. Pharmacological and behavioral approaches to eliminate this reflex have been tried with limited success. This suggested study will test a potent antiemetic drug used in other clinical situations such as antineoplastic treatment. Granisetron is a potential antagonist for the 5-hydroxytryptamine3-receptor - 5HT(3), The drug binds to the receptor and blocks the effect of nausea and vomiting. Kytril mechanism of action was successfully proven for various medical situations as a potential antiemetic agent. Our Center for dental sedation and anesthesia in the oral medicine department have received approval to use Granisetron as an antigagging drug in dental situations based on several pilot studies conducted in other medical centers in different clinical situations such as strabismus corrections, post hysterectomy and others. Our preliminary clinical impression is that pre-emptive IV administration of this drug to patients with increased gag reflex is beneficial. In our research we try to investigate the possibility of using kytril in dental situations. In the first stage of this research we will study the INTRAVENOUS use of this drug and its effects On normal subjects compare them to themselves with placebo. According to the results of this study we will go on to the second stage of the research and try the same drug under oral administration. The purpose of this study is to test the antigagging effect of this drug in a controlled manner in dental situations. Our working hypothesis is that administration of this drug in dental situations with success, will allow many patients to receive good dental care